Display options
Cite
Jully B, Rajkumar T. Potential molecular targets for Ewing's sarcoma therapy. Indian J Med Paediatr Oncol. 2012;33(4):195-202doi: 10.4103/0971-5851.107074.
Jully, B., & Rajkumar, T. (2012). Potential molecular targets for Ewing's sarcoma therapy. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 33(4), 195-202. https://doi.org/10.4103/0971-5851.107074
Jully, Babu, and Rajkumar, Thangarajan. "Potential molecular targets for Ewing's sarcoma therapy." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 33,4 (2012): 195-202. doi: https://doi.org/10.4103/0971-5851.107074
Jully B, Rajkumar T. Potential molecular targets for Ewing's sarcoma therapy. Indian J Med Paediatr Oncol. 2012 Oct;33(4):195-202. doi: 10.4103/0971-5851.107074. PMID: 23580819; PMCID: PMC3618640.
Copy Download .nbib Format: NLM
Share it on

Indian J Med Paediatr Oncol. 2012 Oct;33(4):195-202. doi: 10.4103/0971-5851.107074.

Potential molecular targets for Ewing's sarcoma therapy.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Babu Jully, Thangarajan Rajkumar

Affiliations

  1. Department of Molecular Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India.

PMID: 23580819 PMCID: PMC3618640 DOI: 10.4103/0971-5851.107074

Abstract

Ewing's sarcoma (ES) is a highly malignant tumor of children and young adults. Modern therapy for Ewing's sarcoma combines high-dose chemotherapy for systemic control of disease, with advanced surgical and/or radiation therapeutic approaches for local control. Despite optimal management, the cure rate for localized disease is only approximately 70%, whereas the cure rate for metastatic disease at presentation is less than 30%. Patients who experience long-term disease-free survival are at risk for significant side-effects of therapy, including infertility, limb dysfunction and an increased risk for second malignancies. The identification of new targets for innovative therapeutic approaches is, therefore, strongly needed for its treatment. Many new pharmaceutical agents have been tested in early phases of clinical trials in ES patients who have recurrent disease. While some agents led to partial response or stable disease, the percentages of drugs eliciting responses or causing an overall effect have been minimal. Furthermore, of the new pharmaceuticals being introduced to clinical practice, the most effective agents also have dose-limiting toxicities. Novel approaches are needed to minimize non-specific toxicity, both for patients with recurrence and at diagnosis. This report presents an overview of the potential molecular targets in ES and highlights the possibility that they may serve as therapeutic targets for the disease. Although additional investigations are required before most of these approaches can be assessed in the clinic, they provide a great deal of hope for patients with Ewing's sarcoma.

Keywords: Dose-limiting toxicity; Ewing's sarcoma; molecular targets

References

  1. Ann Oncol. 2005 Apr;16(4):525-37 - PubMed
  2. Thymus. 1991 Aug;18(1):33-41 - PubMed
  3. Oncogene. 2001 Sep 10;20(40):5747-54 - PubMed
  4. N Engl J Med. 1999 Jul 29;341(5):342-52 - PubMed
  5. Oncogene. 2003 Dec 18;22(58):9282-7 - PubMed
  6. Am J Pathol. 1998 Dec;153(6):1937-45 - PubMed
  7. Cancer Res. 2006 Jun 1;66(11):5574-81 - PubMed
  8. Jpn J Clin Oncol. 2007 Feb;37(2):79-89 - PubMed
  9. Expert Opin Investig Drugs. 2010 Aug;19(8):931-45 - PubMed
  10. J Clin Oncol. 2009 Dec 1;27(34):5800-7 - PubMed
  11. Cell Growth Differ. 1996 Apr;7(4):429-37 - PubMed
  12. Cancer Lett. 2007 Aug 28;254(1):1-10 - PubMed
  13. Future Oncol. 2005 Aug;1(4):521-8 - PubMed
  14. Am J Pathol. 1991 Aug;139(2):317-25 - PubMed
  15. Blood. 1994 Jul 15;84(2):595-600 - PubMed
  16. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1235-40 - PubMed
  17. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5752-6 - PubMed
  18. PLoS One. 2008 Jul 09;3(7):e2634 - PubMed
  19. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):919-30 - PubMed
  20. J Neurooncol. 1997 Jan;31(1-2):9-16 - PubMed
  21. Pediatr Blood Cancer. 2008 Jun;50(6):1190-7 - PubMed
  22. J Cancer Res Clin Oncol. 1992;118(4):269-75 - PubMed
  23. Oncogene. 1990 Jul;5(7):1067-70 - PubMed
  24. Science. 2004 Feb 6;303(5659):844-8 - PubMed
  25. Cancer Res. 1997 Sep 15;57(18):3881-5 - PubMed
  26. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1501-8 - PubMed
  27. J Clin Invest. 1990 Dec;86(6):1806-14 - PubMed
  28. Eur J Cancer. 2002 Nov;38(17):2243-51 - PubMed
  29. Cancer Res. 2009 Oct 1;69(19):7662-71 - PubMed
  30. Cancer Lett. 2010 Aug 1;294(1):57-65 - PubMed
  31. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):43-52 - PubMed
  32. Lancet Oncol. 2010 Feb;11(2):129-35 - PubMed
  33. Future Med Chem. 2009 Sep;1(6):1153-71 - PubMed
  34. Cancer Res. 2005 Oct 1;65(19):8984-92 - PubMed
  35. Cancer Res. 1996 Oct 15;56(20):4570-4 - PubMed
  36. Ann Intern Med. 1995 Jan 1;122(1):54-9 - PubMed
  37. Cancer Res. 2006 Oct 15;66(20):9862-9 - PubMed
  38. Nature. 1992 Sep 10;359(6391):162-5 - PubMed
  39. N Engl J Med. 2003 Feb 20;348(8):694-701 - PubMed
  40. Mol Cell Biol. 1993 Dec;13(12):7393-8 - PubMed
  41. Cell Cycle. 2009 Sep 1;8(17):2810-8 - PubMed
  42. Expert Opin Investig Drugs. 2009 Jul;18(7):1025-33 - PubMed
  43. Cancer Res. 2008 Sep 1;68(17):7100-9 - PubMed
  44. Clin Cancer Res. 2006 Nov 15;12(22):6781-90 - PubMed
  45. Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):54-72 - PubMed
  46. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125-35 - PubMed
  47. Cancer Res. 1994 Jun 15;54(12):3253-9 - PubMed
  48. Clin Cancer Res. 2009 May 1;15(9):3058-67 - PubMed
  49. Nat Med. 2009 Jul;15(7):750-6 - PubMed
  50. J Clin Invest. 1997 Jan 15;99(2):239-47 - PubMed
  51. J Pathol. 1994 Mar;172(3):273-8 - PubMed
  52. Cancer Gene Ther. 1995 Sep;2(3):207-12 - PubMed
  53. Mol Cancer Ther. 2009 Oct;8(10):2811-20 - PubMed
  54. Clin Cancer Res. 2011 Feb 1;17(3):494-504 - PubMed
  55. Med Pediatr Oncol. 2000 Dec;35(6):616-8 - PubMed
  56. Hematol Oncol Clin North Am. 1995 Apr;9(2):451-73 - PubMed
  57. Mol Cancer Ther. 2009 Dec;8(12):3341-9 - PubMed
  58. Gene Ther. 2006 Apr;13(7):583-4 - PubMed
  59. Cancer Cell. 2008 May;13(5):454-63 - PubMed
  60. Cancer Res. 1990 Oct 15;50(20):6565-70 - PubMed
  61. Curr Opin Mol Ther. 2010 Jun;12(3):361-71 - PubMed
  62. Int J Clin Exp Pathol. 2010 Mar 19;3(4):338-47 - PubMed
  63. Cancer. 1991 Apr 1;67(7):1886-93 - PubMed
  64. J Clin Invest. 2010 Mar;120(3):668-80 - PubMed
  65. Cancer Res. 2006 Feb 1;66(3):1500-8 - PubMed
  66. Cancer J. 2010 May-Jun;16(3):183-94 - PubMed
  67. Br J Cancer. 2009 Jul 7;101(1):80-90 - PubMed
  68. EMBO J. 1999 Jul 15;18(14):3990-4003 - PubMed
  69. Med Pediatr Oncol. 2002 Mar;38(3):158-64 - PubMed
  70. Pharm Res. 2006 May;23(5):892-900 - PubMed
  71. Oncogene. 1995 Sep 21;11(6):1049-54 - PubMed
  72. Sarcoma. 2011;2011:686985 - PubMed
  73. Cancer Res. 2000 Sep 15;60(18):5134-42 - PubMed
  74. Adv Drug Deliv Rev. 2009 Jul 25;61(9):710-20 - PubMed
  75. Antisense Res Dev. 1994 Summer;4(2):71-9 - PubMed
  76. J Biol Chem. 2003 Apr 25;278(17):15105-15 - PubMed
  77. Ann N Y Acad Sci. 2003 Dec;1002:72-7 - PubMed
  78. Oncogene. 1998 Aug 6;17(5):603-10 - PubMed
  79. EMBO J. 1993 Dec;12(12):4481-7 - PubMed
  80. J Clin Oncol. 2007 Apr 20;25(12):1512-8 - PubMed
  81. Mod Pathol. 2000 Jul;13(7):755-65 - PubMed
  82. Cancer Res. 1998 Sep 15;58(18):4127-31 - PubMed
  83. J Clin Oncol. 1989 Feb;7(2):208-13 - PubMed
  84. Nature. 2006 May 25;441(7092):537-41 - PubMed
  85. Cancer Res. 1993 Dec 15;53(24):5859-63 - PubMed
  86. Int J Cancer. 1999 Apr 20;84(2):192-200 - PubMed

Publication Types